Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Exclusion Criteria

• •The subject has an allergic history of medicine or food；
• •The patient with more serious heart disease, including but not limited to myocardial infarction, cardiomyopathy, valvular disease, malignant arrhythmia；
• •Hb \<9.0 g / 100ml, WBC \<3 ×10\^9/ L, LY \<1.0 x10\^9/ L, platelet \<100,000 / mm3；
• •Patients with immune disease or auto-immune disease (such as Multiple sclerosis, systemic lupus erythematosus，rheumatoid arthritis and inflammatory bowel disease, vitiligo )；
• •The subject has uncontrolled or hard-to-control diseases of liver, or kidney system；
• •Patient with visceral metastases, pathological fractures, spinal cord compression symptoms；
• •Severe pain associated with bone metastases (VAS score ≧ 4 points)；
• •Patient has received immunotherapy (including but not limited to PD-1 / PDL-1, etc.)；
• •patient with irregular hemorrhagic disease；
• •Subject is HIV, hepatitis B virus, hepatitis C virus, Treponema pallidum infection；
• •Subject has uncontrollable seizures, or because of mental loss of self-knowledge and so on；
• •The subject has an history of other malignant tumor；
• •The patient had drug abuse, drug abuse, and long history of alcoholism in the 12 years prior to this trial；
• •The subject has participated in any other clinical trial in the 3 months prior to this trial；
• •The subject has any other unsuitable or adverse condition to be determined by the investigator.